GF
BBIO icon

Gabelli Funds’s BridgeBio Pharma BBIO Stock Holding History

Gabelli Funds’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.86M Hold
65,300
– – 0.03% 526
2026
Q1 		$4.85M Buy
65,300
+3,550
+6% +$257K 0.03% 522
2025
Q4 		$4.72M Sell
61,750
-11,500
-16% -$755K 0.03% 512
2025
Q3 		$3.8M Sell
73,250
-500
-0.7% -$24.4K 0.03% 567
2025
Q2 		$3.18M Buy
73,750
+250
+0.3% +$9.09K 0.02% 611
2025
Q1 		$2.54M Hold
73,500
– – 0.02% 602
2024
Q4 		$2.02M Buy
+73,500
New +$1.9M 0.02% 650
2021
Q4 		– Sell
-6,000
Closed -$281K – 1432
2021
Q3 		$281K Sell
6,000
-2,500
-29% -$134K ﹤0.01% 1180
2021
Q2 		$518K Sell
8,500
-4,200
-33% -$240K ﹤0.01% 1036
2021
Q1 		$782K Buy
+12,700
New +$831K 0.01% 947

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Gabelli Funds's BBIO Position: Q2 2026 in Review

Gabelli Funds held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 65,300 shares worth $4.86M. The position accounts for 0.03% of the portfolio, ranked #526.

Gabelli Funds first reported a position in BBIO in Q1 2021 and has held it in 10 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Gabelli Funds held 65,300 shares of BridgeBio Pharma worth $4.86M as of Q2 2026.
  • Gabelli Funds left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up 0.03% of Gabelli Funds's portfolio in Q2 2026, its #526 holding.
  • Gabelli Funds first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 10 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.